140 related articles for article (PubMed ID: 8425196)
1. Tumor necrosis factor alpha and interleukin 1 alpha induce anchorage independence in v-jun transgenic murine cells.
Vanhamme L; Marshall GM; Schuh AC; Breitman ML; Vogt PK
Cancer Res; 1993 Feb; 53(3):615-21. PubMed ID: 8425196
[TBL] [Abstract][Full Text] [Related]
2. Characterization of sarcoma cell lines from v-jun transgenic mice.
Marshall GM; Vanhamme L
Cancer Res; 1993 Feb; 53(3):622-6. PubMed ID: 8425197
[TBL] [Abstract][Full Text] [Related]
3. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
[TBL] [Abstract][Full Text] [Related]
4. Altered growth and spontaneous transformation of cells cultured from v-jun transgenic mice recapitulate wound-induced multistage tumorigenesis.
Schuh AC; Theodorescu D; Shalaby F; Breitman ML
Cell Growth Differ; 1993 Mar; 4(3):177-84. PubMed ID: 8466856
[TBL] [Abstract][Full Text] [Related]
5. Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts.
Basso J; Briggs J; Findlay C; Bos T
Oncogene; 2000 Oct; 19(42):4876-85. PubMed ID: 11039905
[TBL] [Abstract][Full Text] [Related]
6. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1).
Bader AG; Schneider ML; Bister K; Hartl M
Oncogene; 2001 Nov; 20(51):7524-35. PubMed ID: 11709724
[TBL] [Abstract][Full Text] [Related]
7. Recessive (mediator-) revertants from c-H-ras oncogene-transformed NIH 3T3 cells: tumorigenicity in nude mice and transient anchorage and serum independence of the recovered tumor cells in culture.
Omata-Yamada T; Yamada H; Lengyel P
J Cell Physiol; 1991 Nov; 149(2):214-21. PubMed ID: 1748716
[TBL] [Abstract][Full Text] [Related]
8. Two distinct target cells for v-jun mediated wound tumorigenesis.
Shalaby F; Schuh AC; Breitman ML
Oncogene; 1994 Sep; 9(9):2579-88. PubMed ID: 8058321
[TBL] [Abstract][Full Text] [Related]
9. Activation and inhibition of the AP-1 complex in human breast cancer cells.
Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH
Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534
[TBL] [Abstract][Full Text] [Related]
10. Conditional cell transformation by doxycycline-controlled expression of the ASV17 v-jun allele.
Bader AG; Hartl M; Bister K
Virology; 2000 Apr; 270(1):98-110. PubMed ID: 10772983
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha.
Greenhalgh DA; Wang XJ; Donehower LA; Roop DR
Cancer Res; 1996 Oct; 56(19):4413-23. PubMed ID: 8813135
[TBL] [Abstract][Full Text] [Related]
12. Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice.
Schuh AC; Keating SJ; Monteclaro FS; Vogt PK; Breitman ML
Nature; 1990 Aug; 346(6286):756-60. PubMed ID: 2167455
[TBL] [Abstract][Full Text] [Related]
13. Aberrations in interleukin-1 expression in oncogene-transformed fibrosarcoma lines: constitutive interleukin-1 alpha transcription and manifestation of biological activity.
Douvdevani A; Huleihel M; Segal S; Apte RN
Eur Cytokine Netw; 1991; 2(4):257-64. PubMed ID: 1756231
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response.
Li JJ; Westergaard C; Ghosh P; Colburn NH
Cancer Res; 1997 Aug; 57(16):3569-76. PubMed ID: 9270030
[TBL] [Abstract][Full Text] [Related]
15. Skeletal muscle arises as a late event during development of wound sarcomas in v-jun transgenic mice.
Schuh AC; Keating SJ; Yeung MC; Breitman ML
Oncogene; 1992 Apr; 7(4):667-76. PubMed ID: 1314368
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta and dexamethasone cooperatively enhance c-jun gene expression and inhibit the growth of human monocytoid leukemia cells.
Kanatani Y; Kasukabe T; Okabe-Kado J; Hayashi S; Yamamoto-Yamaguchi Y; Motoyoshi K; Nagata N; Honma Y
Cell Growth Differ; 1996 Feb; 7(2):187-96. PubMed ID: 8822202
[TBL] [Abstract][Full Text] [Related]
17. Induction of growth factor-independence and GM-CSF secretion by the v-src oncogene in murine myeloid cells does not require membrane association of pp60v-src.
Ostermeyer AG; Anderson SM
Exp Hematol; 1996 Feb; 24(2):176-84. PubMed ID: 8641339
[TBL] [Abstract][Full Text] [Related]
18. v-erbA oncogene abrogates growth inhibition of chicken embryo fibroblasts induced by retinoic acid.
Desbois C; Pain B; Guilhot C; Benchaibi M; Ffrench M; Ghysdael J; Madjar JJ; Samarut J
Oncogene; 1991 Nov; 6(11):2129-35. PubMed ID: 1682867
[TBL] [Abstract][Full Text] [Related]
19. The role of transforming growth factor alpha in determining growth factor independence.
Awwad RA; Sergina N; Yang H; Ziober B; Willson JK; Zborowska E; Humphrey LE; Fan R; Ko TC; Brattain MG; Howell GM
Cancer Res; 2003 Aug; 63(15):4731-8. PubMed ID: 12907656
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa B.
Kleinert H; Euchenhofer C; Ihrig-Biedert I; Förstermann U
Mol Pharmacol; 1996 Jan; 49(1):15-21. PubMed ID: 8569701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
